Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product launches and Phase 3 trial results that may lead to higher earnings estimates. The analyst a ...

Sanofi (NASDAQ:SNY) is among the 7 Oversold Pharma Stocks to Buy Now. Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA Sanofi (NASDAQ:SNY) is one of the most oversold stocks. TheFly reported that on February 20, SNY’s price target was lowered at Citi by EUR 5. On the other hand, earlier on February 12, BofA reduced its price target for SNY from EUR 102 to EUR 92 and downgraded the stock from Buy to Neutral. Following the announcement that Belén Garijo, the former CEO of Merck KGaA, wi ...

Core Insights - The article discusses the best long-term low volatility stocks to invest in, highlighting the importance of adapting to a changing economic landscape characterized by increased volatility and the emergence of new investment themes [1][3]. Group 1: Market Trends - Sherry Paul from Morgan Stanley emphasizes a shift from globalization to a "new world order," indicating a need for reimagining supply chains and partnerships, particularly in AI and automation manufacturing in the U.S. [2] - The current economic environment suggests increased volatility ahead, which is seen as a natural part of investing rather than a negative indicator [3]. Group 2: Investment Methodology - The selection of stocks is based on a methodology that identifies long-term stocks with stable fundamentals and a beta below 1, focusing on those with the highest number of hedge fund holders as of Q3 2025 [6]. - The rationale for focusing on hedge fund favorites is that imitating top stock picks can lead to market outperformance, as evidenced by a quarterly newsletter's significant returns since May 2014 [7]. Group 3: Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - The company is enhancing its weight management portfolio through a collaboration with CSPC Pharmaceuticals, focusing on next-generation therapies for obesity and type 2 diabetes [9]. - AstraZeneca will gain exclusive global rights outside of China to CSPC's weight management portfolio, which includes a clinical-ready asset and several preclinical programs [10][11]. - **International Business Machines Corporation (NYSE:IBM)**: - The company received a price target increase from Argus to $360, driven by strong Q4 performance attributed to GenAI and hybrid cloud momentum [13]. - RBC Capital also raised its price target to $361, citing solid free cash flow performance and exposure to secular themes, particularly from the z17 mainframe refresh cycle [14].

Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the undervalued stocks by Goldman Sachs, indicating potential investment opportunities [1] Analyst Sentiment - As of January 16, 2026, approximately 60% of analysts maintain a bullish outlook on Merck, despite a modest consensus price target of $115.00, reflecting a 3.60% upside [2] - Wolfe Research upgraded Merck from 'Peer Perform' to 'Outperform' on January 8, 2026, raising the price target to $135.00, driven by updates in the valuation model that consider the company's late-stage pipeline and potential label expansions [3] Strategic Developments - Merck is reportedly exploring the acquisition of Revolution Medicines, a cancer drug developer, with a potential deal valued between $28 billion and $32 billion, which would enhance its oncology pipeline amid patent risks for Keytruda expected later in the decade [4] - The company has a strong oncology franchise and is expanding its late-stage pipeline across various therapeutic areas, positioning itself favorably in the healthcare market [5]

Core Insights - Oakmark International Fund's fourth-quarter 2025 investor letter highlights a return of 4.83%, underperforming the MSCI World ex USA Index's gain of 5.20% [1] - The fund's top contributors were in the healthcare and financial sectors, while consumer staples detracted from performance [1] Company Analysis: AstraZeneca PLC - AstraZeneca PLC (NASDAQ:AZN) is a leading biopharmaceutical company with a market capitalization of $298.709 billion, focusing on prescription medicines for various diseases [2][3] - The stock closed at $96.34 on January 14, 2026, with a one-month return of 6.32% and a 52-week gain of 43.98% [2] - The company is recognized for its strong on-market portfolio and a leading late-stage pipeline, which are expected to drive growth [3] - CEO Pascal Soriot is noted for his exceptional leadership and innovative culture within the company, contributing to its robust R&D capabilities [3] Investment Sentiment - Despite AstraZeneca's potential, it is not among the top 30 most popular stocks among hedge funds, with 54 hedge fund portfolios holding the stock at the end of Q3, an increase from 48 in the previous quarter [4] - The company faces challenges due to regulatory concerns in the U.S., which have affected its stock price, creating a buying opportunity for investors [3]

Core Viewpoint - Merck has promoted Johanna Herrmann to senior vice president and chief communications officer, expanding her responsibilities in corporate communications and global health contributions [1][2][3] Group 1: Leadership Changes - Johanna Herrmann was previously the senior vice president and head of global communications, a position she assumed in January 2025 [1] - Herrmann joined Merck in 2021 as chief of staff to Cristal Downing, who recently left the company to join Insulet [4][5] Group 2: Responsibilities and Focus Areas - In her new role, Herrmann will oversee corporate communications, employee and executive communications, global media relations, and enterprise social media [2] - Additional responsibilities include communications for Merck Research Laboratories and Merck Animal Health, as well as managing the company's global reputation [3] Group 3: Company Performance - In the third quarter of 2025, Merck reported revenue of $17.28 billion, reflecting a 4% increase from the same period the previous year [7] - The company posted a net income of $5.79 billion for the quarter, compared to $3.16 billion in the year-earlier period [7]

Core Insights - Merck & Co. is recognized as a significant and influential entity in the global pharmaceutical industry, known for its research-intensive biopharmaceutical operations [1] Group 1: Company Overview - Merck & Co. engages in the discovery, development, manufacturing, and marketing of a diverse range of prescription medicines, vaccines, and biologics [1]

Core Insights - Merck & Co. is recognized as a significant and influential entity in the global pharmaceutical industry, known for its research-intensive biopharmaceutical operations [1] Group 1: Company Overview - Merck & Co. engages in the discovery, development, manufacturing, and marketing of a diverse range of prescription medicines, vaccines, and biologics [1]

Company Overview - Johnson & Johnson (JNJ) is a global healthcare conglomerate with a market cap of $455 billion, headquartered in New Brunswick, New Jersey, and founded in 1886. The company operates in innovative prescription medicines, advanced surgical and medical technologies, and legacy consumer brands [1]. Performance Metrics - JNJ has outperformed the broader market in 2025, with stock gains of 30.6% year-to-date and 17.6% over the past 52 weeks, compared to the S&P 500 Index's gains of 16.3% and 17.7% respectively [2]. - In the healthcare sector, JNJ has also outperformed the Health Care Select Sector SPDR Fund (XLV), which has risen 4.9% in 2025 and experienced a 2.6% decline over the past 52 weeks [3]. Financial Results - For Q3 2025, JNJ reported a revenue growth of 6.8% year-over-year to $24 billion and an adjusted EPS increase of 16% to $2.80, indicating solid growth in both top and bottom lines. The company raised its full-year 2025 revenue guidance midpoint to approximately $93.2 billion while maintaining its adjusted EPS guidance at around $10.85 [4]. - Analysts project an adjusted EPS of $10.86 for fiscal 2025, reflecting an 8.8% year-over-year increase, with JNJ having exceeded Wall Street's earnings expectations in each of the last four quarters [5]. Analyst Ratings - The stock has a consensus "Moderate Buy" rating, with 25 analysts covering it, including 13 "Strong Buys," two "Moderate Buys," and 10 "Holds" [5]. - A month ago, the configuration was slightly less bullish, with 11 analysts giving "Strong Buy" recommendations. J.P. Morgan analyst Chris Schott reiterated a "Hold" rating on JNJ with a price target of $205 [6]. - The mean price target for JNJ is $202.35, indicating a modest 7.1% upside potential, while the highest target of $225 suggests a notable 19.1% premium to current price levels [6].

Core Insights - Novartis AG is recognized for its strong market position in branded pharmaceuticals, particularly in oncology, immunology, cardiovascular, renal, metabolic, and neurology sectors [1] - The company has undergone significant restructuring, including the recent spinoff of its Sandoz generics and biosimilars division, focusing solely on innovative medicines which now represent about 80% of revenue [1] - Novartis generates over 50% of its revenue from the Americas, approximately 30% from Europe, and nearly 20% from other regions [1] Financial Performance - Oncology accounts for 30% of Novartis' revenues, while immunology contributes almost 20%, and cardiovascular, renal, and metabolic areas also account for nearly 20% [1] - Mature branded products in non-core therapy areas contribute over 20% of the company's revenues [1] - Prior to the Sandoz spinoff, innovative medicines accounted for 85% of core operating income [1]